| 0.466 -0.018 (-3.72%) | 02-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.78 | 1-year : | 0.95 |
| Resists | First : | 0.66 | Second : | 0.81 |
| Pivot price | 0.55  |
|||
| Supports | First : | 0.43 | Second : | 0.35 |
| MAs | MA(5) : | 0.52 |
MA(20) : | 0.55 |
| MA(100) : | 0.48 |
MA(250) : | 0.6 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 18 |
D(3) : | 23.7 |
| RSI | RSI(14): 42.2 |
|||
| 52-week | High : | 1.34 | Low : | 0.31 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ YCBD ] has closed below the lower bollinger band by 9.5%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ YCBD ] is to continue within current trading range. Bollinger Bands are 0.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.5 - 0.5 | 0.5 - 0.5 |
| Low: | 0.45 - 0.45 | 0.45 - 0.45 |
| Close: | 0.46 - 0.47 | 0.47 - 0.47 |
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. It also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. The company distributes its products through its e-commerce Website, third-party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. It has a research partnership with the University of Mississippi to identify novel cannabinoids. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was incorporated in 2015 and is headquartered in Charlotte, North Carolina.
Sat, 15 Feb 2025
cbdMD, Inc. (AMEX:YCBD) Q1 2025 Earnings Call Transcript - Insider Monkey
Fri, 14 Feb 2025
cbdMD Inc (YCBD) Q1 2025 Earnings Call Highlights: Achieving Profitability and Debt-Free Status By GuruFocus - Investing.com Canada
Fri, 07 Feb 2025
cbdMD, Inc. to Host Conference Call to Discuss December 31, 2024 First Quarter of Fiscal Year 2025 Results - Yahoo Finance
Fri, 07 Feb 2025
cbdMD Earnings: Strategic Financial Review & Market Position Update Coming Feb 13 - StockTitan
Wed, 15 Jan 2025
cbdMD Eliminates All Debt Through Early Note Conversion, Strengthens Financial Position - StockTitan
Fri, 03 Jan 2025
cbdMD Faces NYSE American Delisting Risk Over $2M Equity Requirement Shortfall - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 4 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 19.1 (%) |
| Held by Institutions | 2.2 (%) |
| Shares Short | 159 (K) |
| Shares Short P.Month | 158 (K) |
| EPS | -10.9 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.8 |
| Profit Margin | -94.2 % |
| Operating Margin | -7.4 % |
| Return on Assets (ttm) | -15.8 % |
| Return on Equity (ttm) | -135.1 % |
| Qtrly Rev. Growth | -15.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 5.48 |
| EBITDA (p.s.) | -1.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | 5 (M) |
| PE Ratio | -0.05 |
| PEG Ratio | 0 |
| Price to Book value | 0.58 |
| Price to Sales | 0.08 |
| Price to Cash Flow | -2.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|